Who is sponsoring NCT03259464?

NCT03259464 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT03259464?

Interventions: BI 685509, Placebo.

What is the status of NCT03259464?

NCT03259464 is currently COMPLETED.

Last reviewed 2018-07-05 · How we verify

This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated

NCT03259464 PHASE1 COMPLETED

The primary objective of this trial is to investigate the safety and tolerability of BI 685509 in healthy male subjects following oral administration of multiple rising doses. Secondary objectives are the exploration of the pharmacokinetics (PK) and pharmacodynamics (PD) of BI 685509 in healthy Chinese and Japanese subjects.

Details

Lead sponsor	Boehringer Ingelheim
Phase	PHASE1
Status	COMPLETED
Enrolment	72
Start date	Mon Sep 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat May 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Healthy

Interventions

BI 685509
Placebo

Countries

Japan, South Korea